VistaGen Therapeutics Inc... (VTGN)
NASDAQ: VTGN
· Real-Time Price · USD
3.40
0.09 (2.87%)
At close: Aug 18, 2025, 3:59 PM
3.50
2.94%
After-hours: Aug 18, 2025, 07:59 PM EDT
2.87% (1D)
| Bid | 3.4 |
| Market Cap | 104.31M |
| Revenue (ttm) | 486K |
| Net Income (ttm) | -51.42M |
| EPS (ttm) | -1.79 |
| PE Ratio (ttm) | -1.9 |
| Forward PE | -1.78 |
| Analyst | n/a |
| Ask | 3.54 |
| Volume | 1,107,933 |
| Avg. Volume (20D) | 380,740 |
| Open | 3.35 |
| Previous Close | 3.31 |
| Day's Range | 3.31 - 3.58 |
| 52-Week Range | 1.90 - 3.79 |
| Beta | 0.40 |
About VTGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VTGN
Website n/a
Next Earnings Release
VistaGen Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago · fool.com
Vistagen (VTGN) Q1 R&D Expense Jumps 54%Vistagen (VTGN) Q1 R&D Expense Jumps 54%
1 month ago · businesswire.com
Vistagen Appoints Elissa Cote as Chief Corporate Development OfficerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
2 months ago · seekingalpha.com
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptVistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - ...
2 months ago · businesswire.com
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
